J
John D. Hainsworth
Researcher at Sarah Cannon Research Institute
Publications - 590
Citations - 48783
John D. Hainsworth is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Chemotherapy & Carboplatin. The author has an hindex of 85, co-authored 585 publications receiving 45112 citations. Previous affiliations of John D. Hainsworth include Vanderbilt University Medical Center & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
TL;DR: Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points.
Journal ArticleDOI
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic,Michael R. Migden,Anthony E. Oro,Luc Dirix,Karl D. Lewis,John D. Hainsworth,James A. Solomon,Simon Yoo,Sarah T. Arron,Philip Friedlander,Philip Friedlander,Ellen S. Marmur,Charles M. Rudin,Anne Lynn S. Chang,Jennifer A. Low,Howard Mackey,Robert L. Yauch,Richard A. Graham,Josina C. Reddy,Axel Hauschild +19 more
TL;DR: A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.
Journal ArticleDOI
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne Pavel,John D. Hainsworth,Eric Baudin,Marc Peeters,Dieter Hörsch,Robert Winkler,Judith Klimovsky,David Lebwohl,Valentine Jehl,Edward M. Wolin,Kjell Öberg,Eric Van Cutsem,James C. Yao +12 more
TL;DR: Everolimus plus octreotide LAR, compared with placebo plusOctreotide Larry, improved progression-free survival in patients with advanced neuroendocrine tumours associated with carcinoid syndrome.